Despite the success of antiretroviral therapy (ART) for people living with HIV, lifelong
treatment is required and there is no cure. HIV can integrate in the host genome and persist …

Immunotherapy is leading a paradigm shift in the treatment of various diseases, including
tumors, auto‐immune diseases, and infectious diseases. However, the limited response rate …

Transplantation of B cells engineered ex vivo to secrete broadly neutralizing antibodies
(bNAbs) has shown efficacy in disease models. However, clinical translation of this …

Given the absence of an effective vaccine for protection against HIV-1 infection, passive
immunization strategies that utilize potent broadly neutralizing antibodies (bnAbs) to block …

Mice adoptively transferred with mouse B cells edited via CRISPR to express human
antibody variable chains could help evaluate candidate vaccines and develop better …

Due to their unique longevity and capacity to secrete high levels of protein, plasma B cells
have the potential to be used as a cell therapy for protein replacement. Here, we show that …

Since their discovery, antibodies capable of broad neutralisation have been at the forefront
of HIV-1 research and are of particular interest due to in vivo passive transfer studies …

Silica nanosheets (SN) derived from natural vermiculite (Verm) were successfully
incorporated into polyethersulfone–polyvinylpyrrolidone (PES–PVP) polymer to fabricate …

ABSTRACT HIV viremia can be controlled by chronic antiretroviral therapy. As a potentially
single-shot alternative, B cells engineered by CRISPR/Cas9 to express anti-HIV broadly …

Antibody immunodominance refers to the preferential and asymmetric elicitation of
antibodies against specific epitopes on a complex protein antigen. Traditional vaccination …